血尿安胶囊联合头孢他啶治疗尿路感染的临床研究
|
摘要
目的探讨血尿安胶囊联合头孢他啶治疗尿路感染的临床疗效。方法选取2015年8月—2018年8月在广州中医药大学第一临床医学院进行治疗的84例尿路感染患者,根据住院号的奇偶数分为对照组和治疗组,每组各42例。对照组静脉滴注注射用头孢他啶,2 g与0.9%氯化钠注射液100 mL配伍,2次/d。治疗组患者在对照组治疗基础上口服血尿安胶囊,4粒/次,3次/d。两组均连续治疗2周。观察两组的临床疗效,比较两组治疗细菌培养转阴率、症状转阴时间、血清学指标。结果治疗后,对照组和治疗组的总有效率分别是80.95%、97.62%,两组比较差异具有统计学意义(P<0.05)。治疗后,对照组和治疗组的尿细菌培养转阴率分别是73.81%、95.24%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组临床症状消退时间、退热时间、尿检白细胞转阴时间均显著短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)水平均较治疗前显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组这些炎症因子水平低于对照组,两组比较差异具有统计学意义(P<0.05)。结论血尿安胶囊联合头孢他啶治疗尿路感染具有较好的临床疗效,可显著改善患者临床症状,降低机体促炎因子水平,提高尿细菌清除率,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Xueniaoan Capsules combined with ceftazidime in treatment of urinary tract infection. Methods Patients(84 cases) with urinary tract infection in the First Clinical Medical College of Guangzhou University of Traditional Chinese Medicine from August 2015 to August 2018 were divided into control(42 cases) and treatment(42 cases) groups according to the odd and even number of admission Numbers. Patients in the control group were iv administered with Ceftazidime for injection, 2 g was compatible with 0.9% sodium chloride injection 100 m L, twice daily. Patients in the treatment group were po administered with Xueniaoan Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the bacterial culture conversion rate,symptom conversion time, and serological indexes in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.95% and 97.62%, respectively, and there were differences between two groups(P < 0.05).After treatment, the urine bacteria culture negative rate in the control and treatment groups were 73.81% and 95.24%, respectively, and there were differences between two groups(P < 0.05). The clinical symptoms regression time, antipyretic time, and urine white blood cell conversion time in the treatment group were significantly shorter than those in the control group, and there were differences between two groups(P < 0.05). After treatment, hs-CRP, IL-6, IL-8 TNF-α, and PCT in two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, the levels of those inflammatory factors in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Xueniaoan Capsules combined with ceftazidime has significant effect in treatment of urinary tract infection, and can significantly improve the clinical symptoms, and reduce proinflammatory factors, and improve the rate of bacterial clearance in urine, which has a certain clinical application value.
Objective To investigate the clinical efficacy of Xueniaoan Capsules combined with ceftazidime in treatment of urinary tract infection. Methods Patients(84 cases) with urinary tract infection in the First Clinical Medical College of Guangzhou University of Traditional Chinese Medicine from August 2015 to August 2018 were divided into control(42 cases) and treatment(42 cases) groups according to the odd and even number of admission Numbers. Patients in the control group were iv administered with Ceftazidime for injection, 2 g was compatible with 0.9% sodium chloride injection 100 m L, twice daily. Patients in the treatment group were po administered with Xueniaoan Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the bacterial culture conversion rate,symptom conversion time, and serological indexes in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.95% and 97.62%, respectively, and there were differences between two groups(P < 0.05).After treatment, the urine bacteria culture negative rate in the control and treatment groups were 73.81% and 95.24%, respectively, and there were differences between two groups(P < 0.05). The clinical symptoms regression time, antipyretic time, and urine white blood cell conversion time in the treatment group were significantly shorter than those in the control group, and there were differences between two groups(P < 0.05). After treatment, hs-CRP, IL-6, IL-8 TNF-α, and PCT in two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, the levels of those inflammatory factors in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Xueniaoan Capsules combined with ceftazidime has significant effect in treatment of urinary tract infection, and can significantly improve the clinical symptoms, and reduce proinflammatory factors, and improve the rate of bacterial clearance in urine, which has a certain clinical application value.
引文
[1]谌贻璞.肾内科学[M].第2版.北京:人民卫生出版社,2015:96.
[2]吴忠玮.头孢他啶联合三金片治疗急性尿路感染临床[J].天津药学,2011,23(6):43-44.
[3]王学,何敏,张俊,等.血尿安胶囊抗尿路感染的药效学研究[J].中药药理与临床,2016,32(4):97-101.
[4]葛均波,徐永健.内科学[M].北京:人民卫生出版社,2013:498-499.
[5]孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社,2002:136-137.
[6]张林落,金妙文,卢秋成,等.国医大师周仲瑛教授辨治尿路感染经验探幽[J].中华中医药杂志,2018,33(9):3923-3925.
[7]李莉,辛晓妮.血清降钙素原、C反应蛋白对尿路感染的诊断价值[J].山东医药,2013,53(21):40-42.
[8]彭璇,柯贵宝.尿路感染患者血清和肽素、IL-6、PCT水平的变化及临床意义[J].实用临床医学,2017,7(1):13-15.
[9]樊均明,李幼姬,唐世聪.白介素-8及其在肾脏病研究中的意义[J].国外医学:泌尿系统分册,1994,4(2):53-55.
[10]吕志敢,郭政.肿瘤坏死因子的研究进展[J].山西医科大学学报,2006,37(3):311-314
[11]彭健桥,李帼宁,仇杭佳.血清降钙素原测定在尿路感染中的应用[J].国际检验医学杂志,2013,34(3):278-279.
[2]吴忠玮.头孢他啶联合三金片治疗急性尿路感染临床[J].天津药学,2011,23(6):43-44.
[3]王学,何敏,张俊,等.血尿安胶囊抗尿路感染的药效学研究[J].中药药理与临床,2016,32(4):97-101.
[4]葛均波,徐永健.内科学[M].北京:人民卫生出版社,2013:498-499.
[5]孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社,2002:136-137.
[6]张林落,金妙文,卢秋成,等.国医大师周仲瑛教授辨治尿路感染经验探幽[J].中华中医药杂志,2018,33(9):3923-3925.
[7]李莉,辛晓妮.血清降钙素原、C反应蛋白对尿路感染的诊断价值[J].山东医药,2013,53(21):40-42.
[8]彭璇,柯贵宝.尿路感染患者血清和肽素、IL-6、PCT水平的变化及临床意义[J].实用临床医学,2017,7(1):13-15.
[9]樊均明,李幼姬,唐世聪.白介素-8及其在肾脏病研究中的意义[J].国外医学:泌尿系统分册,1994,4(2):53-55.
[10]吕志敢,郭政.肿瘤坏死因子的研究进展[J].山西医科大学学报,2006,37(3):311-314
[11]彭健桥,李帼宁,仇杭佳.血清降钙素原测定在尿路感染中的应用[J].国际检验医学杂志,2013,34(3):278-279.